Source: Clinical and experimental rheumatology. Unidade: FM
Subjects: MIOSITE, FÁRMACOS IMUNOSSUPRESSORES, EVENTO ADVERSO A MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOUZA, R. C. de et al. Efficacy and safety of leflunomide as an adjuvant drug in refractory dermatomyositis with primarily cutaneous activity. Clinical and experimental rheumatology, v. 35, n. 6, p. 1011-1013, 2017Tradução . . Disponível em: http://observatorio.fm.usp.br/handle/OPI/25488. Acesso em: 03 jun. 2024.APA
Souza, R. C. de, Souza, F. H. C. de, Miossi, R., & Shinjo, S. M. O. (2017). Efficacy and safety of leflunomide as an adjuvant drug in refractory dermatomyositis with primarily cutaneous activity. Clinical and experimental rheumatology, 35( 6), 1011-1013. Recuperado de http://observatorio.fm.usp.br/handle/OPI/25488NLM
Souza RC de, Souza FHC de, Miossi R, Shinjo SMO. Efficacy and safety of leflunomide as an adjuvant drug in refractory dermatomyositis with primarily cutaneous activity [Internet]. Clinical and experimental rheumatology. 2017 ; 35( 6): 1011-1013.[citado 2024 jun. 03 ] Available from: http://observatorio.fm.usp.br/handle/OPI/25488Vancouver
Souza RC de, Souza FHC de, Miossi R, Shinjo SMO. Efficacy and safety of leflunomide as an adjuvant drug in refractory dermatomyositis with primarily cutaneous activity [Internet]. Clinical and experimental rheumatology. 2017 ; 35( 6): 1011-1013.[citado 2024 jun. 03 ] Available from: http://observatorio.fm.usp.br/handle/OPI/25488
